Stryker (NYSE:SYK) said yesterday that it closed its acquisition of Arrinex and its Clarifix cryoablation technology intended for treating chronic rhinitis.
Kalamazoo, Mich.-based Stryker said that Menlo Park, Calif.-based Arrinex was founded in 2013 and began commercializing the Clarifix technology in late 2017.
Stryker said that the acquisition will expand its ENT portfolio and that the Clarifix technology will address a large segment of the ENT market in which the company does not currently compete.
“The acquisition of Arrinex is highly complementary to Stryker’s ENT portfolio, which is part of our Neurotechnology business. This acquisition aligns with our focus on providing ENT physicians with new technologies that deliver more treatment options and better patient outcomes,” neurotechnology, instruments & spine group prez Spencer Stiles said in a press release.
Earlier this month, Stryker said that it launched a select voluntary recall of Lifepak 15 monitor/defibrillators over issues in which the device locks up and may not deliver life-saving therapy, adding that it has received six reports of deaths related to the issue.